ABN Amro Investment Solutions Invests $849,000 in Biogen Inc. $BIIB

ABN Amro Investment Solutions acquired a new position in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, HoldingsChannel reports. The firm acquired 4,826 shares of the biotechnology company’s stock, valued at approximately $849,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. IFP Advisors Inc raised its stake in shares of Biogen by 10.0% in the fourth quarter. IFP Advisors Inc now owns 1,206 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 110 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Biogen in the fourth quarter valued at approximately $3,321,000. HighTower Advisors LLC grew its holdings in shares of Biogen by 18.2% in the fourth quarter. HighTower Advisors LLC now owns 11,959 shares of the biotechnology company’s stock valued at $2,105,000 after acquiring an additional 1,843 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of Biogen in the fourth quarter valued at approximately $291,000. Finally, Mission Wealth Management LP grew its holdings in shares of Biogen by 5.3% in the fourth quarter. Mission Wealth Management LP now owns 1,822 shares of the biotechnology company’s stock valued at $321,000 after acquiring an additional 92 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s stock may be getting some support from analyst commentary suggesting the recent sell-off could be overdone, with one report saying the trial results were better than first reported and that longer-term optimism remains intact. Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
• Neutral Sentiment: Denali said it will keep running a separate Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant, which preserves some optionality for the broader program but does not offset the failure in idiopathic Parkinson’s disease. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• Negative Sentiment: The failed Parkinson’s trial has also sparked investor concern and legal scrutiny, with multiple alerts and investigations following the disclosure, adding another overhang to Biogen shares. Investor Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Analysts Set New Price Targets

Several research firms have recently issued reports on BIIB. Evercore began coverage on Biogen in a report on Friday, May 15th. They issued an “outperform” rating for the company. Canaccord Genuity Group upped their target price on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $225.00 target price (up from $214.00) on shares of Biogen in a report on Friday, May 15th. Guggenheim upped their target price on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, HSBC upped their target price on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $215.62.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $193.76 on Monday. The stock has a fifty day simple moving average of $185.48 and a two-hundred day simple moving average of $180.95. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The firm has a market cap of $28.61 billion, a price-to-earnings ratio of 20.79, a price-to-earnings-growth ratio of 1.71 and a beta of 0.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the company earned $3.02 earnings per share. Biogen’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.